Skip to main content

Table 1 Clinical findings of 10 patients with PHSC

From: Imaging and clinical features of primary hepatic sarcomatous carcinoma

NO.

Age (y)

Sex

Histolgic diagnosis

Confirm

Underlying disease

AFP

CA19–9

TNMa

Treatment after diagnosis

Follow up result

1

55

M

S-ICC

Resection

CH-A

–

–

T4N0M1

Operation

Progress (1 M) death (2 M)

2

47

M

S-ICC

Resection

CH-A

–

+

T3N0M0

Operation

Progress (2 M) death (6 M)

3

39

M

S-HCC

Resection

CH-B

+

+

T1N0M0

TACE and Operation

Tumor-free (16 M)

4

55

M

S-HCC

Biopsy

Normal

–

–

T1N0M0

TACE and RFA

Tumor-free (21 M)

5

51

M

S-HCC

Resection

CH-B

+

+

T3N1M0

Operation and TACE

Tumor-free (12 M)

6

56

M

S-HCC

Biopsy

CH-B

+

–

T3N1M1

TACE

Death (4 M)

7

56

M

S-HCC

Biopsy

CH-B

–

–

T4N1M1

TACE

Death (5 M)

8

62

F

S-HCC

Resection

CH-B

–

+

T2N0M0

Operation

Recurrence (8 M) alive (10 M)

9

60

M

S-HCC

Resection

CH-B

+

–

T1N0M0

Operation

Tumor-free (24 M)

10

57

M

S-HCC–CC

Resection

CH-B

+

–

T3N1M0

Operation and PMA

Recurrence (6 M) alive (36 M)

  1. + yes/present/positive, − no/absent/negative
  2. CH-A chronic alcoholic hepatitis, CH-B chronic viral hepatitis B, CH-C chronic viral hepatitis C, AFP alpha-fetoprotein (positive defined as > 7 ng/mL), CA19–9 carbohydrate antigen 19–9 (positive defined as > 27 U/mL), RFA radiofrequency ablation, TACE transcatheter arterial chemoembolization, PMA percutaneous microwave ablation
  3. a AJCC TNM Staging of Liver Tumors (7th edition, 2010)